Results 41 to 50 of about 838,232 (233)

A mRNA Vaccine for Crimean–Congo Hemorrhagic Fever Virus Expressing Non-Fusion GnGc Using NSm Linker Elicits Unexpected Immune Responses in Mice

Viruses
Crimean–Congo hemorrhagic fever (CCHF), caused by Crimean–Congo Hemorrhagic virus (CCHFV), is listed in the World Health Organization’s list of priority diseases.
Tong Chen, Zhe Ding, Xuejie Li, Yingwen Li, Jiaming Lan, Gary Wong   +5 more
doaj   +1 more source

A favorable outcome of dengue hemorrhagic fever despite poor prognostic indices: a case report with a mix of classic and unusual clinical and laboratory features

The Pan African Medical Journal, 2019
The report describes a 32-year-old man with dengue hemorrhagic fever presenting with acute onset high-grade intermittent fever with chills and rigors, headache, myalgia, abdominal pain, and vomiting.
Olukemi Adekanmbi, Sulaiman Lakoh
doaj   +1 more source

The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging [PDF]

, 2013
Rift Valley fever virus (RVFV, family Bunyaviridae) is a mosquito-borne pathogen of both livestock and humans, found primarily in Sub-Saharan Africa and the Arabian Peninsula.
Benjamin Brennan (522804), Brennan, Benjamin, Richard M. Elliott, Richard M Elliott, Welch Stephen R., Elliott, Richard M., Benjamin Brennan, Elliott Richard M., Richard M. Elliott (252934), Stephen R Welch, Stephen R. Welch (522805), Stephen R. Welch, Welch, Stephen R., Brennan Benjamin   +13 more
core   +1 more source

HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities

American Journal of Hematology, EarlyView.
ABSTRACT Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ0) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to ...
Halima Bello‐Manga, Shehu Umar Abdullahi, Hoda Hassab, Biobele Brown, Videlis Nduba, Jessie Githanga, Adeseye Michael Akinsete, Amal El‐Beshlawy, Diana Hanna, Catherine Segbefia, Iheanyi Okpala, Azza Tantawy, Bernhards Ogutu, Venée N. Tubman, Vivian Paintsil, Yasser Wali, Mohammed Essa, Paul Telfer, Sandy Dixon, Anne Hickman, Jennifer F. Doss, Mark W. Davis, Jeremy Rupon, Fenella J. Kirkham, R. Clark Brown, on behalf of the HOPE Kids 2 Investigators, Amal El‐Beshlawy, Mohamed Badr, Diana Hanna*, Hoda Hassab, Azza Tantawy, Vivian Paintsil, Catherine Segbefia, Raffaella Colombatti, Daniela Cuzzubbo, Silverio Perrotta, Jessie Githanga, Videlis Nduba, Bernhards Ogutu, Shehu Umar Abdullahi, Adeseye Michael Akinsete, Halima Bello‐Manga, Biobele Brown, Iheanyi Okpala, Yasser Wali, Mohammed Essa, Banu Kaya, Paul Telfer, Ofelia Alvarez, Natasha Archer, Shayla Bergmann, R Clark Brown, Andrew Campbell, Carlton Dampier*, Richard Hurwitz, Erin Jackson, Janet Kwiatkowski, Melissa M. McNaull*, Venée N. Tubman   +58 more
wiley   +1 more source

Crimean-Congo hemorrhagic fever with severe bradycardia treated with Theophylline [PDF]

Revista da Sociedade Brasileira de Medicina Tropical
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral hemorrhagic fever caused by Nairovirus and characterized by fever, myalgia, arthralgia, and hemorrhagic manifestations. Severe bradycardia is a rare complication of the disease. We present a 30-
Murat Aydın, Nurten Nur Aydın
doaj   +1 more source

Treatment of Crimean-Congo hemorrhagic fever

, 2007
Ribavirin is a synthetic purine nucleoside analog with a modified base and D-ribose sugar, also known as virazol, first synthesized by Sidwell and colleagues in 1972 [43, 49] (Fig. 19-1).

core   +1 more source

Immune Modulatory Therapy for Severe Dengue Hemorrhagic Fever in a Patient With Mitochondrial Complex I Deficiency: A Case Report

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Dengue virus (DENV) poses a serious global health challenge, particularly in cases of dengue hemorrhagic fever (DHF). Patients with preexisting mitochondrial disorders may be at increased risk for complications due to the specific impact of DENV on mitochondrial‐dependent cellular processes and immune function.
Audra N. Iness, Ameya S. Walimbe, Emily R. Strouphauer, Michio Hirano, Alejandro D. Iglesias, Valentina Emmanuele, Caitlin C. Griffin, Sheldon L. Kaplan, William A. Gomes, Karen K. Moeller, Stephen F. Kralik, Fernando Scaglia   +11 more
wiley   +1 more source

Duck Orbivirus and Egg Production: A Newly Identified Duck Orbivirus Is the Etiological Agent of Egg Production Decline in Chinese Breeder Ducks

Animal Research and One Health, EarlyView.
Field samples from breeder duck farms with egg‐production decline were subjected to viral detection, genome sequencing, and virus isolation. Experimental infection demonstrated that duck orbivirus (DORV) causes a significant and persistent reduction in egg production in breeder ducks.
Bing Li, Jianhua Wang, Xuezhi Cui, Xinxing Chu, You Wang, Dongmin Hao, Mingqing Xu, Haixia Chang, Huihui Li, Mingtian Mao, Mian Wu, Chengguang Lu, Jing Tang, Suyun Liang, Zhanbao Guo, Zhengkui Zhou, Youxiang Diao, Shuisheng Hou, Yi Tang   +18 more
wiley   +1 more source

Evaluation of antigen and antibody assays for surveillance of Lassa virus in peri-domestic rodents in southeastern Sierra Leone: a cross-sectional study

The Lancet Microbe
Summary: Background: Lassa fever, caused by Lassa mammarenavirus (LASV), is a rodent-borne disease endemic to west Africa. Zoonotic surveillance of LASV provides epidemiological insights into its potential presence.
Allison R Smither, PhD, James Koninga, Franklyn B Kanneh, MS, Momoh Foday, Matthew L Boisen, PhD, Nell G Bond, PhD, Mambu Momoh, MS, John D Sandi, PhD, Lansana Kanneh, HD, Foday Alhasan, BS, Ibrahim M Kanneh, HD, Mohamed S Yillah, Donald S Grant, MBChB, Duane J Bush, MS, Diana K S Nelson, BS, Kaitlin M Cruz, MD, Raphaëlle Klitting, PhD, Matthias G Pauthner, PhD, ProfPhD Kristian G Andersen, PhD, ProfPhD Jeffrey G Shaffer, PhD, Luis M Branco, PhD, ProfPhD Robert W Cross, PhD, ProfMD John S Schieffelin, PhD, ProfPhD Robert F Garry, PhD   +23 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source